Anti-inflammatory lipoxin A 4 is an endogenous allosteric enhancer of CB 1 cannabinoid receptor
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Allosteric modulation of G-protein–coupled receptors represents a key goal of current pharmacology. In particular, endogenous allosteric modulators might represent important targets of interventions aimed at maximizing therapeutic efficacy and reducing side effects of drugs. Here we show that the anti-inflammatory lipid lipoxin A 4 is an endogenous allosteric enhancer of the CB 1 cannabinoid receptor. Lipoxin A 4 was detected in brain tissues, did not compete for the orthosteric binding site of the CB 1 receptor (vs. 3 H-SR141716A), and did not alter endocannabinoid metabolism (as opposed to URB597 and MAFP), but it enhanced affinity of anandamide at the CB1 receptor, thereby potentiating the effects of this endocannabinoid both in vitro and in vivo. In addition, lipoxin A 4 displayed a CB 1 receptor-dependent protective effect against β-amyloid (1–40)-induced spatial memory impairment in mice. The discovery of lipoxins as a class of endogenous allosteric modulators of CB 1 receptors may foster the therapeutic exploitation of the endocannabinoid system, in particular for the treatment of neurodegenerative disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators
Serhan, C. N., Chiang, N., & Van Dyke, T. E. (2008) · Nature Reviews Immunology · doi:10.1038/nri2294 · Cited by 2,932
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077 · cited 5×
“Activation of CB1 receptors reduces cAMP levels, inhibits voltagedependent Ca channels, and activates inward-rectifying K channels, resulting in reduced neuronal excitability and presynaptic inhibition of neurotransmitter release (1, 2).”
BackgroundInfluentialThe molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 1×
“These results add a player in brain endocannabinoid signaling, which might help in clarifying unsolved issues in the field, such as the differential mechanism of action of different endocannabinoids (54).”
BackgroundCB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity
Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutiérrez, S. O., van der Stelt, M., et al. (2003) · Science · doi:10.1126/science.1088208 · Cited by 1,208 · cited 1×
“Moreover, knowing that ajulemic acid induces the release of LXA4 acting as a proresolving mediator in inflammation (30); that LXA4 increases the affinity of AEA for the CB1 receptors (this study); and that certain metabolites of AEA degradation by lipoxygenases retain affinity for the CB1 receptor (46) or reduce AEA m…”
BackgroundSelf-citationThe Endocannabinoid System Controls Key Epileptogenic Circuits in the Hippocampus
Monory, K., Massa, F., Egertová, M., Eder, M., Blaudzun, H., Westenbroek, R., Kelsch, W., Jacob, W., Marsch, R., Ekker, M., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.07.006 · Cited by 706
Self-citationCannabinoid physiology and pharmacology: 30 years of progress
Howlett, A. C., Breivogel, C. S., Childers, S. R., Deadwyler, S. A., Hampson, R. E., & Porrino, L. J. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.030 · Cited by 608 · cited 6×
“LXA4 increases twofold the potency of AEA to generate CB1-dependent K + currents in the oocytes [F(2,17) = 7.”
BackgroundInfluentialTanimura, A., Yamazaki, M., Hashimotodani, Y., Uchigashima, M., Kawata, S., Abe, M., Kita, Y., Hashimoto, K., Shimizu, T., Watanabe, M., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.01.021 · Cited by 472 · cited 1×
“Furthermore, AEA is only a partial agonist, whereas 2-AG is a full agonist of the CB1 receptor (4, 35), suggesting that 2-AG is the “true” endocannabinoid in the CNS to which the retrograde messengermediated neuroplasticity can be attributed (36).”
BackgroundEljaschewitsch, E., Witting, A., Mawrin, C., Lee, T., Schmidt, P. M., Wolf, S., Hoertnagl, H., Raine, C. S., Schneider-Stock, R., Nitsch, R., et al. (2006) · Neuron · doi:10.1016/j.neuron.2005.11.027 · Cited by 445 · cited 1×
“Moreover, knowing that ajulemic acid induces the release of LXA4 acting as a proresolving mediator in inflammation (30); that LXA4 increases the affinity of AEA for the CB1 receptors (this study); and that certain metabolites of AEA degradation by lipoxygenases retain affinity for the CB1 receptor (46) or reduce AEA m…”
Background
Cited by
Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators
Serhan, C. N., & Levy, B. D. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97943 · Cited by 1,344
“LXA 4 can also serve as an endogenous allosteric regulator of the endocannabinoid receptor CB1 (115).”
BackgroundZou, S., & Kumar, U. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030833 · Cited by 1,343
Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan‐Wright, E. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13250 · Cited by 1,039
“To date, the best-characterized allosteric modulators of CB1 receptors are the positive allosteric modulator lipoxin A4 (Pamplona et al., 2012) and the negative allosteric modulators (NAMs) ORG27569 and PSNCBAM-1 (Price et al.”
BackgroundCannabinoids and the expanded endocannabinoid system in neurological disorders
Cristino, L., Bisogno, T., & Di Marzo, V. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0284-z · Cited by 970
The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution
Serhan, C. N., Chiang, N., & Dalli, J. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.03.004 · Cited by 583
Metadata
- Authors
- Pamplona, F. A., Ferreira, J., Menezes de Lima, O., Duarte, F. S., Bento, A. F., Forner, S., Villarinho, J. G., Bellocchio, L., Wotjak, C. T., Lerner, R., Monory, K., Lutz, B., Canetti, C., Matias, I., Calixto, J. B., Marsicano, G., Guimarães, M. Z. P., & Takahashi, R. N.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2012-11-12
- Volume
- 109
- Issue
- 51
- Pages
- 21134-21139
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2152921151
- Cited by
- 179
- References
- 10
- FWCI
- 9.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.